Medtronic plc, a global leader in healthcare technology, and DASI Simulations, a leader in AI-driven predictive modeling and digital-twin technology, today announced a strategic partnership to enhance access to DASI technology to optimize outcomes for patients undergoing transcatheter aortic valve replacement (TAVR) in the United States..

全球医疗技术领导者美敦力公司与人工智能驱动的预测建模和数字孪生技术领导者DASI Simulations今天宣布建立战略合作伙伴关系，以增加对DASI技术的使用，从而优化美国经导管主动脉瓣置换术（TAVR）患者的结果。

This program marks a significant step forward in both Medtronic’s and DASI’s mission to deliver innovative, patient-specific care. By integrating DASI Simulations’ advanced AI-based predictive modeling and digital twin technology into the TAVR workflow, clinicians will gain access to independent and device-agnostic actionable insights that support more precise, individualized treatment decisions for patients living with aortic stenosis..

该计划标志着美敦力和DASI在提供创新的、针对患者的护理任务中迈出了重要的一步。通过将DASI模拟的先进基于人工智能的预测建模和数字孪生技术整合到TAVR工作流程中，临床医生将获得独立且与设备无关的可行见解，这些见解支持对患有主动脉瓣狭窄的患者做出更精确、更个性化的治疗决策。

“Effective pre-case planning is essential to achieving optimal outcomes in TAVR,” said Matthew Summers, MD, interventional cardiologist at Sentara Heart Hospital. “Integrating DASI’s predictive modeling into our workflow has allowed us to better visualize anatomy, anticipate risks, and tailor valve decisions to each patient.

“有效的术前规划对于在TAVR中取得最佳结果至关重要，”Sentara Heart Hospital的心脏介入医生Matthew Summers博士说道。“将DASI的预测建模整合到我们的工作流程中，让我们能够更好地可视化解剖结构、预测风险，并根据每位患者的情况定制瓣膜决策。”

It’s helped us focus on individual factors like annular rupture, coronary occlusion, and paravalvular leak, while also planning for future reinterventions. As TAVR complexity grows, it becomes increasingly important to have tools that support truly personalized decision-making. This includes making informed choices between surgical aortic valve replacement and TAVR, as well as which TAVR valve, to ensure the best possible care.”.

它帮助我们关注个别因素，如环形破裂、冠状动脉阻塞和瓣周漏，同时也为未来的再次干预做好规划。随着TAVR复杂性的增加，拥有支持真正个性化决策的工具变得越来越重要。这包括在外科主动脉瓣置换术和TAVR之间做出明智的选择，以及选择哪种TAVR瓣膜，以确保提供最佳的护理。

“Partnering with Medtronic accelerates our mission to bring scalable, AI-powered planning tools to structural heart programs nationwide,” said Teri Sirset, MS, founder, president, and chief executive officer of DASI Simulations. “Together, we’re demonstrating how predictive modeling can drive operational efficiency, support clinical decision-making, and elevate the standard of care.

“与美敦力合作加速了我们将可扩展的、由人工智能驱动的规划工具推向全国结构性心脏项目的目标，”DASI Simulations公司的创始人、总裁兼首席执行官Teri Sirset表示，“我们共同展示了预测建模如何推动运营效率、支持临床决策并提升护理标准。”

This collaboration reflects the growing demand for data-driven solutions that empower heart teams to deliver more confident, personalized treatment decisions.”.

这种合作反映了对数据驱动解决方案日益增长的需求，这些解决方案能够助力心脏团队做出更自信、更个性化的治疗决策。”

DASI’s FDA-cleared platform leverages real patient computerized tomography (CT) anatomies and retrospective outcomes to simulate multiple transcatheter heart valve (THV) deployment scenarios. Using these data-driven reports – rooted in independent device-agnostic, patient-specific predictive modeling – will help mitigate human error, predict complications, and optimize long-term management for structural heart patients..

DASI公司获FDA批准的平台利用真实患者的计算机断层扫描（CT）解剖结构和回顾性结果，模拟多种经导管心脏瓣膜（THV）部署场景。使用这些基于独立于设备、针对患者特定的预测建模的数据驱动报告，将有助于减少人为错误、预测并发症，并优化结构性心脏病患者的长期管理。

“The future of TAVR lies in delivering patient-specific, data-driven care that spans the full patient journey, from therapy awareness and innovation to procedural excellence and options for future intervention,” said Jorie Soskin, vice president and general manager of the Structural Heart business within the Cardiovascular portfolio at Medtronic.

“TAVR 的未来在于提供针对患者的、数据驱动的护理，贯穿患者的整个治疗过程，从治疗意识和创新到手术卓越以及未来干预的选择，”美敦力心血管产品组合中结构性心脏业务的副总裁兼总经理 Jorie Soskin 说道。

“Our partnership highlights our commitment to lead this future, allowing heart teams to utilize AI driven pre-procedural planning to enhance patient outcomes, streamline workflow, and support patient-specific valve selection.'.

“我们的合作突显了我们引领未来的决心，使心脏团队能够利用人工智能驱动的术前规划来改善患者预后、简化工作流程，并支持针对患者特定的瓣膜选择。”

Participating sites will receive full support from both Medtronic Structural Heart and DASI Simulations teams. The program is designed to demonstrate the clinical and operational value of integrating simulation-based planning to enable device agnostic, patient-specific TAVR care.

参与的站点将获得来自美敦力结构性心脏病团队和DASI模拟团队的全力支持。该计划旨在展示整合基于仿真的规划所带来的临床和运营价值，以实现与设备无关、针对患者的个性化TAVR护理。

“We are entering a new era in structural heart care, guided by predictive AI models that help the physician determine the best treatment personalized for each patient, rather than relying on statistical norms. This shift to precision medicine will transform how we treat structural heart diseases,” said Lakshmi Dasi, PhD, founder and chief technology officer at DASI Simulations.

“我们正在进入结构性心脏病护理的新时代，由预测性人工智能模型指导，帮助医生确定每个患者的最佳个性化治疗方案，而不是依赖统计学标准。这种向精准医疗的转变将改变我们治疗结构性心脏病的方式，”DASI Simulations创始人兼首席技术官拉克什米·达西博士说道。

“DASI is the pioneer for AI-based predictive modeling for TAVR, and our platform is designed to support unbiased and device agnostic decision-making with the patient at the center that will ultimately support more confident, personalized interventions.”.

“DASI是基于人工智能的TAVR预测建模的先驱，我们的平台旨在支持以患者为中心的无偏见且与设备无关的决策，最终将支持更自信、个性化的干预。”

About DASI

关于DASI

Founded in 2020, DASI Simulations, based in Dublin, Ohio, performs advanced individualized computational predictive modeling for heart surgery candidates. The modeling is powered by artificial intelligence and computer vision to help cardiologists and heart surgeons better plan for the structural heart procedures and any potential complications, which leads to improved patient outcomes and reduced costs associated with structural heart disease surgeries.

总部位于俄亥俄州都柏林的DASI Simulations公司成立于2020年，专门为心脏手术候选人进行先进的个体化计算预测建模。该建模由人工智能和计算机视觉提供支持，帮助心脏病学家和心脏外科医生更好地规划结构性心脏手术及任何潜在并发症，从而改善患者预后并降低与结构性心脏病手术相关的成本。

The company currently has two FDA-cleared products – PrecisionTAVI™ and DASI Dimensions™. DASI’s pioneering predictive modeling reports are reimbursed by CMS. For more information, visit .

该公司目前拥有两款经FDA批准的产品——PrecisionTAVI™ 和 DASI Dimensions™。DASI的开创性预测建模报告由CMS报销。欲了解更多信息，请访问。

www.dasisim.com

www.dasisim.com

or email

或电子邮件

news@dasisim.com

新闻@dasisim.com

.

。

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找和发现解决方案，勇敢地应对人类面临的最严峻的健康问题。我们的使命——减轻痛苦、恢复健康、延长生命——团结了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多元化的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

我们致力于推动以洞察力为导向的护理、以人为本的体验以及为我们的世界带来更好的结果，因此请对我们有更多期待。在我们所做的一切中，我们正在创造非凡。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow Medtronic on

关注美敦力

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力向证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果有重大差异。

Contacts:

联系人：

Kimberly Powell

金伯利·鲍威尔

Medtronic Public Relations

美敦力公共关系

+1-202-498-2601

+1-202-498-2601

Ryan Weispfenning

瑞安·魏斯芬宁

Medtronic Investor Relations

美敦力投资者关系

+1-763-505-4626

+1-763-505-4626

Kelly Arledge

凯莉·阿莱奇

DASI Media Relations

DASI媒体关系

+1-614-205-0339

+1-614-205-0339